JP2016514165A5 - - Google Patents

Download PDF

Info

Publication number
JP2016514165A5
JP2016514165A5 JP2016503188A JP2016503188A JP2016514165A5 JP 2016514165 A5 JP2016514165 A5 JP 2016514165A5 JP 2016503188 A JP2016503188 A JP 2016503188A JP 2016503188 A JP2016503188 A JP 2016503188A JP 2016514165 A5 JP2016514165 A5 JP 2016514165A5
Authority
JP
Japan
Prior art keywords
compound
cell
androgen
inhibition
androgen receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016503188A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016514165A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/029667 external-priority patent/WO2014153215A1/en
Publication of JP2016514165A publication Critical patent/JP2016514165A/ja
Publication of JP2016514165A5 publication Critical patent/JP2016514165A5/ja
Pending legal-status Critical Current

Links

JP2016503188A 2013-03-14 2014-03-14 アンドロゲン受容体下方制御剤及びその使用 Pending JP2016514165A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361782383P 2013-03-14 2013-03-14
US61/782,383 2013-03-14
PCT/US2014/029667 WO2014153215A1 (en) 2013-03-14 2014-03-14 Androgen receptor down-regulating agents and uses thereof

Publications (2)

Publication Number Publication Date
JP2016514165A JP2016514165A (ja) 2016-05-19
JP2016514165A5 true JP2016514165A5 (enExample) 2017-04-20

Family

ID=51583862

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016503188A Pending JP2016514165A (ja) 2013-03-14 2014-03-14 アンドロゲン受容体下方制御剤及びその使用

Country Status (13)

Country Link
US (2) US9884067B2 (enExample)
EP (2) EP4066841A1 (enExample)
JP (1) JP2016514165A (enExample)
KR (1) KR20150127720A (enExample)
CN (1) CN105682662A (enExample)
AU (1) AU2014236135A1 (enExample)
BR (1) BR112015023098A2 (enExample)
CA (1) CA2904170A1 (enExample)
IL (1) IL240820A0 (enExample)
MX (1) MX2015012274A (enExample)
RU (1) RU2015137617A (enExample)
SG (1) SG11201507093WA (enExample)
WO (1) WO2014153215A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
CA2904170A1 (en) 2013-03-14 2014-09-25 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
WO2014165815A2 (en) 2013-04-04 2014-10-09 University Of Maryland, Baltimore Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
JP2016528252A (ja) 2013-08-12 2016-09-15 トーカイ ファーマシューティカルズ, インコーポレイテッド アンドロゲン標的治療を使用する新生物障害の処置のためのバイオマーカー
US10675289B2 (en) * 2014-10-02 2020-06-09 University Of Maryland, Baltimore Methods of treating pancreatic cancer
CN105713063A (zh) * 2014-12-02 2016-06-29 重庆安格龙翔医药科技有限公司 一种阿比特龙乙酸酯的制备方法
US10682362B2 (en) 2015-10-14 2020-06-16 Wayne State University Treatments and diagnostics for cancers
CN112851741B (zh) * 2016-02-19 2022-10-25 深圳市塔吉瑞生物医药有限公司 一种取代的甾体类化合物及其应用
CN107365343A (zh) * 2016-05-12 2017-11-21 四川海思科制药有限公司 一种苯并咪唑雄甾衍生物及其制备方法和医药用途
EP3474848A4 (en) 2016-06-22 2020-04-15 University of Maryland, Baltimore PROCESS FOR PRODUCING NEW GALETERONE ANALOGS AND USES THEREOF
WO2019023651A2 (en) 2017-07-28 2019-01-31 Massachusetts Institute Of Technology MODULATORS OF THE SMALL MOLECULE ANDROGEN RECEPTOR
CN107857790A (zh) * 2017-12-14 2018-03-30 中国药科大学 一种新型甾体类雄激素受体抑制剂、制备方法及其医药用途
CN116917009A (zh) 2021-02-19 2023-10-20 美国迈胜医疗系统有限公司 用于粒子治疗系统的机架
CN116444599A (zh) * 2022-01-07 2023-07-18 中国科学院上海药物研究所 甾体类化合物及制备方法和用途

Family Cites Families (228)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2664423A (en) 1952-03-12 1953-12-29 Searle & Co 4-(cyclopentanopolyhydrophenanthr-17-yl) imidazoles and derivatives thereof
GB972672A (en) 1960-01-14 1964-10-14 Ciba Ltd Pharmaceutical preparations containing compounds of the androstane series
US3060174A (en) 1960-01-14 1962-10-23 Ciba Geigy Corp Esters of the androstane series and process for their manufacture
US3313809A (en) 1965-03-05 1967-04-11 Sterling Drug Inc Steroido[21, 20-d]isoxazoles
US3317520A (en) 1965-03-05 1967-05-02 Sterling Drug Inc Steroido[20, 21-c]pyrazoles and intermediates
DE1493169A1 (de) 1965-09-03 1969-06-04 Schering Ag Verfahren zur Herstellung von 5 beta-Bisnorcholanderivaten
US3480621A (en) 1967-01-17 1969-11-25 Phytogen Prod Inc Steroid ketal
CH621803A5 (enExample) 1974-08-08 1981-02-27 Siphar Sa
JPS563000Y2 (enExample) 1976-07-27 1981-01-23
JPS563000A (en) 1979-06-20 1981-01-13 Green Cross Corp:The Water-soluble cholesterol derivative
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4469689A (en) 1983-03-30 1984-09-04 The Upjohn Company Sulfonate containing ester prodrugs of corticosteroids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5843708A (en) 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
IT1216687B (it) 1988-04-01 1990-03-08 Boehringer Biochemia Srl Complessi di platino (ii), loro preparazione e impiego come antitumorali.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5028726A (en) 1990-02-07 1991-07-02 The University Of Vermont And State Agricultural College Platinum amine sulfoxide complexes
US5264428A (en) 1990-02-16 1993-11-23 Kanoldt Arzneimittel Gmbh Use of stigmasta-4-en-3-one in the treatment of androgen dependent diseases
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
US5300294A (en) 1990-06-27 1994-04-05 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
US5385936A (en) 1990-07-12 1995-01-31 The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services Gossypol acetic acid for the treatment of cancer
US5023264A (en) 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
AU637247B2 (en) 1990-08-01 1993-05-20 Merrell Dow Pharmaceuticals Inc. 4-amino-delta4-steroids and their use as 5alpha-reductase inhibitors
US5023263A (en) 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
AU664976B2 (en) 1990-08-29 1995-12-14 Gene Pharming Europe Bv Homologous recombination in mammalian cells
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5233036A (en) 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
EP0580860B2 (en) 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Method of manufacturing solid dispersion
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5162333A (en) 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
GB9125660D0 (en) 1991-12-03 1992-01-29 Smithkline Beecham Plc Novel compound
US5264427A (en) 1992-01-29 1993-11-23 Research Corporation Technologies, Inc. 20-substituted pregnene derivatives and their use as androgen synthesis inhibitors
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
WO1993020097A1 (en) 1992-03-31 1993-10-14 British Technology Group Ltd. 17-substituted steroids useful in cancer treatment
US5237064A (en) 1992-05-20 1993-08-17 Merck & Co., Inc. Process for producing 7β-substituted-aza-5αandrostan-3-ones
AU672978B2 (en) 1992-05-20 1996-10-24 Merck & Co., Inc. 4-azasteroid 5-alpha-reductase inhibitors
ZA935111B (en) 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
US6042828A (en) 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
DE4232681C2 (de) 1992-09-29 1994-11-24 Sigma Tau Ind Farmaceuti 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5489680A (en) 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5411967A (en) 1992-10-13 1995-05-02 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
CA2161531A1 (en) 1993-04-30 1994-11-10 Donald C. Malins Dna profiles as an indicator of cellular redox potential and cancer risk
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
JP4105761B2 (ja) 1993-11-19 2008-06-25 アボット・ラボラトリーズ ラパミシン(マクロライド)の半合成類似体免疫調節剤
US5385909A (en) 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5385910A (en) 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
CZ284650B6 (cs) 1993-12-17 1999-01-13 Novartis Ag Nové demethoxyderiváty rapamycinu, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
US5637310A (en) 1993-12-20 1997-06-10 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
US5389639A (en) 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US6974666B1 (en) 1994-10-21 2005-12-13 Appymetric, Inc. Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA
US5491231A (en) 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5599695A (en) 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
KR100400620B1 (ko) 1995-06-09 2004-02-18 노파르티스 아게 라파마이신유도체
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
EP0862436A1 (en) 1995-10-19 1998-09-09 Merck & Co., Inc. 16-substituted-6-aza-steroid 5-alpha-reductase inhibitors
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
AU2253397A (en) 1996-01-23 1997-08-20 Affymetrix, Inc. Nucleic acid analysis techniques
EP0937159A4 (en) 1996-02-08 2004-10-20 Affymetrix Inc SPECIATION OF MICROORGANISMS FROM MICROPLATES AND CHARACTERIZATION OF THE PHENOTYPES THEREOF
US6458530B1 (en) 1996-04-04 2002-10-01 Affymetrix Inc. Selecting tag nucleic acids
EP0937082A2 (en) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US6368598B1 (en) 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer
US5994334A (en) 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
US5994335A (en) 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
ATE479425T1 (de) 1998-04-10 2010-09-15 Mitsubishi Chem Corp Sialsäure-derivate enthaltende feste dispersion
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
ES2306646T3 (es) 1999-02-09 2008-11-16 Pfizer Products Inc. Composiciones de farmacos basicos con biodisponibilidad incrementada.
ES2219388T3 (es) 1999-08-24 2004-12-01 Ariad Gene Therapeutics, Inc. 28-epi-rapalogos.
CA2382545C (en) 1999-08-27 2013-08-13 Phylos, Inc. Methods for encoding and sorting in vitro translated proteins
CN1390220A (zh) 1999-09-17 2003-01-08 艾博特股份有限两合公司 作为治疗剂的激酶抑制剂
EP1228083A2 (en) 1999-09-30 2002-08-07 Hollis-Eden Pharmaceuticals Inc. Therapeutic treatment of androgen receptor driven conditions
EP1239835B1 (en) 1999-12-23 2013-03-20 Bend Research, Inc. Pharmaceutical compositions providing enhanced drug concentrations
MY138883A (en) 2000-08-29 2009-08-28 Government Of Malaysia As Represented By The Ministry Of Science Tehnology And Innovation Malaysia Use of asiatic acid for treatment of cencer
US20020165381A1 (en) 2000-11-30 2002-11-07 Isabelle Ahrens-Fath Human androgen receptor variants
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
WO2002083139A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
WO2002083675A2 (en) 2001-04-10 2002-10-24 Merck Sharp & Dohme Limited Inhibitors of akt activity
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
US20030054053A1 (en) 2001-09-20 2003-03-20 Charles Young Methods and compositions for inhibiting the proliferation of prostate cancer cells
ES2283593T3 (es) 2001-10-12 2007-11-01 Johns Hopkins University Analogos de oxima poco calcemicos de 1alfa,25-dihidroxi vitamina d3.
SE0103424D0 (sv) 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
US20070015713A1 (en) 2005-07-14 2007-01-18 Voyager Pharmaceutical Corporation Methods for treating prostate cancer
PL371593A1 (en) 2002-02-01 2005-06-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
WO2003063822A2 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
WO2003086394A1 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
CA2480880C (en) 2002-04-08 2011-03-22 Merck & Co., Inc. Inhibitors of akt activity
PT1530457E (pt) 2002-08-12 2009-11-06 Bend Res Inc Composições farmacêuticas de fármacos na forma semi-ordenada e de polímeros
AU2003270087B2 (en) 2002-09-03 2009-04-23 Georgetown University Akt inhibitors, pharmaceutical compositions, and uses thereof
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
AU2003284981B2 (en) 2002-10-30 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
TW200500360A (en) 2003-03-01 2005-01-01 Astrazeneca Ab Hydroxymethyl compounds
CN1809351A (zh) 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
ATE446752T1 (de) 2003-04-24 2009-11-15 Merck & Co Inc Hemmer der akt aktivität
CN1809354A (zh) 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
JP4673300B2 (ja) 2003-04-24 2011-04-20 メルク・シャープ・エンド・ドーム・コーポレイション Akt活性の阻害剤
US7439268B2 (en) 2003-07-18 2008-10-21 Idexx Laboratories Compositions containing prodrugs of florfenicol and methods of use
ATE513555T1 (de) 2003-07-29 2011-07-15 Dompe Spa Pharmazeutische kombination aus g-csf und plgf für blutstammzellen
CA2535944A1 (en) 2003-08-22 2005-03-03 University Of Virginia Patent Foundation Blockade of mtor to prevent a hormonal adaptive response
US7605120B2 (en) 2003-10-22 2009-10-20 Amgen Inc. Antagonists of the brandykinin B1 receptor
MXPA06005578A (es) 2003-11-17 2006-08-11 Pfizer Prod Inc Compuestos de pirrolopirimidina utiles en el tratamiento del cancer.
JP4585201B2 (ja) 2004-01-23 2010-11-24 丸善製薬株式会社 アンドロゲン受容体結合阻害剤、養毛剤、皮脂分泌抑制剤及び前立腺肥大抑制剤
WO2005085227A1 (en) 2004-03-02 2005-09-15 Smithkline Beecham Corporation Inhibitors of akt activity
US20050239751A1 (en) 2004-03-26 2005-10-27 Rigel Pharmaceuticals, Inc. Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
WO2005098446A2 (en) 2004-03-31 2005-10-20 The Johns Hopkins University Biomarkers for ovarian cancer
CN1953747A (zh) 2004-04-08 2007-04-25 顶标公司 二苯基-吲哚-2-酮化合物及其在治疗癌症中的用途
CA2561315A1 (en) 2004-04-09 2005-10-27 Merck & Co., Inc. Inhibitors of akt activity
US7655649B2 (en) 2004-04-09 2010-02-02 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US7604947B2 (en) 2004-06-09 2009-10-20 Cornell Research Foundation, Inc. Detection and modulation of cancer stem cells
US20060013873A1 (en) 2004-07-16 2006-01-19 Chih-Chiang Yang Bioadhesive dosage form of steroids
AU2005290081B2 (en) 2004-08-23 2010-12-02 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
CN101133036B (zh) * 2004-09-30 2010-10-13 詹森药业有限公司 可用作选择性雄激素受体调节剂(sarms)的新苯并咪唑衍生物
CA2597456A1 (en) 2005-02-14 2006-08-31 Merck & Co., Inc. Inhibitors of akt activity
NZ561571A (en) 2005-03-02 2009-09-25 Univ Maryland Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
US20060204588A1 (en) 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
DE102005011786A1 (de) 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
CN101155588A (zh) 2005-04-12 2008-04-02 默克公司 Akt活性的抑制剂
HRP20130429T1 (en) 2005-06-10 2013-06-30 Merck Sharp & Dohme Corp. Inhibitors of akt activity
AU2006292212A1 (en) 2005-09-19 2007-03-29 The Johns Hopkins University Biomarker for prostate cancer
CA2630271C (en) 2005-11-17 2014-04-08 Osi Pharmaceuticals, Inc. Fused bicyclic mtor inhibitors
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
WO2007087395A2 (en) 2006-01-25 2007-08-02 Osi Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
US7943732B2 (en) 2006-06-05 2011-05-17 Intrexon Corporation AKT ligands and polynucleotides encoding AKT ligands
NZ573979A (en) 2006-07-06 2012-02-24 Array Biopharma Inc Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
JP2010502640A (ja) 2006-08-30 2010-01-28 ノバルティス アクチエンゲゼルシャフト mTORシグナル伝達を調節する組成物および方法
US8129184B2 (en) 2006-09-26 2012-03-06 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008047201A2 (en) 2006-10-17 2008-04-24 Pfizer Products Inc. Solid dispersion comprising a poorly water soluble drug
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
WO2008070823A2 (en) 2006-12-07 2008-06-12 University Of South Florida Substrate-mimetic akt inhibitor
US7960435B2 (en) 2006-12-15 2011-06-14 University Of Maryland, Baltimore Anti-cancer agents and androgen inhibition activity compound
US7807393B2 (en) 2007-01-29 2010-10-05 Northwestern University Biomarkers for prostate cancer
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
LT2481409T (lt) 2007-03-07 2018-10-25 Abraxis Bioscience, Llc Nanodalelės, apimančios rapamiciną ir albuminą, kaip priešvėžinį agentą
WO2008154382A1 (en) 2007-06-06 2008-12-18 University Of Maryland, Baltimore Hdac inhibitors and hormone targeted drugs for the treatment of cancer
WO2008154402A2 (en) 2007-06-06 2008-12-18 University Of Maryland, Baltimore Hdac inhibitors and hormone targeted drugs for the treatment of cancer
US20090012045A1 (en) 2007-06-26 2009-01-08 Rigel Pharmaceuticals, Inc. Methods of Treating Cell Proliferative Disorders
US20090047252A1 (en) 2007-06-29 2009-02-19 Gilead Sciences, Inc. Antiviral compounds
EP2240483B8 (en) 2008-01-09 2013-04-03 Array Biopharma, Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
WO2009114658A2 (en) 2008-03-12 2009-09-17 University Of Maryland, Baltimore Androgen receptor inactivation contributes to antitumor efficacy of cyp17 inhibitors in prostate cancer
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
GB2470700B (en) 2008-03-25 2012-08-08 Univ Maryland C-17 heteroaryl steroidal CYP17 inhibitors
US8785423B2 (en) 2008-04-14 2014-07-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
ES2566750T3 (es) 2008-04-16 2016-04-15 The Johns Hopkins University Método para determinar el riesgo de recidiva de cáncer de próstata
EP2311842A3 (en) 2008-06-24 2011-07-13 Takeda Pharmaceutical Company Limited PI3K/M TOR inhibitors
WO2010089763A2 (en) 2008-06-30 2010-08-12 Reliance Life Sciences Pvt. Ltd. Poly(n-vinyl caprolactam-co-acrylamide) microparticles for controlled release applications
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
JP2011529080A (ja) 2008-07-24 2011-12-01 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション,インコーポレイテッド 癌幹細胞を標的とする治療法
JP5616892B2 (ja) 2008-09-12 2014-10-29 ダコ・デンマーク・エー/エス 前立腺癌バイオマーカー
US8133724B2 (en) 2008-09-17 2012-03-13 University Of Maryland, Baltimore Human androgen receptor alternative splice variants as biomarkers and therapeutic targets
US8841422B2 (en) 2008-09-17 2014-09-23 University Of Maryland, Baltimore Human androgen receptor alternative splice variants
RU2538683C2 (ru) 2008-10-31 2015-01-10 Новартис Аг КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ (Р13К) И ИНГИБИТОРА mTOR
CN101607985B (zh) 2008-12-24 2013-03-27 中国科学院生物物理研究所 抗人cea的单克隆抗体,包含其的组合物,及其用途
CN102686600A (zh) 2009-02-05 2012-09-19 托凯药业股份有限公司 甾体cyp17抑制剂/抗雄激素物质的新型药物前体
WO2010091299A2 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel combination cancer therapies
GB2479693B (en) 2009-02-05 2014-04-09 Tokai Pharmaceuticals Inc Steroidal CYP17 inhibitors and their use in the treatment of cancer and prostate hyperplasia
WO2010104705A1 (en) 2009-03-12 2010-09-16 Merck Sharp & Dohme Corp. Inhibitors of akt activity
PT3130396T (pt) 2009-03-27 2021-05-12 Bend Res Inc Processo de secagem por pulverização
AU2010279398A1 (en) 2009-08-07 2012-03-08 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer
JP5956928B2 (ja) * 2009-11-13 2016-07-27 トーカイ ファーマシューティカルズ,インク. 哺乳類のステロイドの代謝物質
WO2011112581A1 (en) 2010-03-08 2011-09-15 Regents Of The University Of Minnesota Androgen receptor isoforms and methods
US8703712B2 (en) 2010-03-18 2014-04-22 The Uab Research Foundation Targeting cancer stem cells with DR5 agonists
CA2804210A1 (en) 2010-07-06 2012-01-12 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of androgen receptor by double-stranded rna
US20120028972A1 (en) 2010-07-30 2012-02-02 Lilly Wong Biomarker assays for detecting or measuring inhibition of tor kinase activity
BR112013017635A2 (pt) 2010-12-16 2016-10-11 Biomarin Pharm Inc inibidores de cyp11b, cyp17 e/ou cyp21
WO2012103456A2 (en) 2011-01-27 2012-08-02 Board Of Regents, The University Of Texas System Polycyclic beta lactam derivatives for the treatment of cancer
US9594086B2 (en) 2011-03-22 2017-03-14 The Johns Hopkins University Biomarkers for aggressive prostate cancer
CN103813794A (zh) 2011-07-18 2014-05-21 拓凯制药公司 用于治疗前列腺癌的新型组合物及方法
US20140329786A1 (en) 2011-11-30 2014-11-06 Astrazeneca Ab Combination treatment of cancer
JP2015503508A (ja) 2011-12-22 2015-02-02 トーカイ ファーマシューティカルズ,インク. PI3K/mTOR阻害剤を使用する併用療法のための方法および組成物
EA029563B1 (ru) 2012-07-27 2018-04-30 Арагон Фармасьютикалз, Инк. Способы и композиции для определения резистентности к терапии, направленной на андрогенный рецептор
WO2014047285A1 (en) 2012-09-19 2014-03-27 Paraskevi Giannakakou Identifying taxane sensitivity in prostate cancer patients
CA2904170A1 (en) 2013-03-14 2014-09-25 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
JP2016528252A (ja) 2013-08-12 2016-09-15 トーカイ ファーマシューティカルズ, インコーポレイテッド アンドロゲン標的治療を使用する新生物障害の処置のためのバイオマーカー
CA2959336A1 (en) 2014-08-25 2016-03-03 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics
WO2016172517A1 (en) 2015-04-24 2016-10-27 Tokai Pharmaceuticals, Inc. Methods of treating prostate cancer

Similar Documents

Publication Publication Date Title
JP2016514165A5 (enExample)
EP2751086A4 (en) KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHOD OF USE THEREOF
WO2014113620A3 (en) Phthalazinones and isoquinolinones as rock inhibitors
JP2010116404A5 (enExample)
EP2750677A4 (en) KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHOD OF USE THEREOF
EP2528441A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
MX361542B (es) Compuestos de morfinan.
WO2012177481A3 (en) Fibroblast growth factor receptor inhibition for the treatment of disease
MX2013008225A (es) Composicion farmaceutica que comprende agonistas de opioide y antagonista secuestrado.
EP2736337A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
PH12014500943A1 (en) Combination treatment of cancer
JP2015500225A5 (enExample)
EP2833879A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
JP2009506080A5 (enExample)
MX389742B (es) Composiciones y metodos para reducir eventos adversos cardiovasculares graves.
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
WO2014016754A3 (en) Pharmaceutical compositions of proton pump inhibitor
MX350304B (es) Metodos para reducir la ingesta excesiva o comer compulsivamente.
WO2012082862A3 (en) Androgen receptor inhibitors and methods of use thereof
LT3044223T (lt) 2,3-dihidro-1h-inden-1-ono dariniai, kaip su retinoine rūgštimi susijusio orfaninio receptoriaus gama (ror-gama) antagonistai, skirti išsėtinės sklerozės gydymui
JP2016501845A5 (enExample)
GB201210686D0 (en) V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
MX371102B (es) Nuevos derivados de bencimidazol como agentes antihistaminicos.
WO2011109367A3 (en) Methods and compositions for treating or preventing symptoms of hormonal variations
WO2013017910A8 (en) Extended release pharmaceutical compositions containing paliperidone